Moonwalk Biosciences, a biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing.

The financing was co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures. Proceeds will support advancement of Moonwalk's lead obesity candidate, MW101, into first-in-human clinical studies in late 2027, expand the Company's pipeline of tissue-targeted siRNA medicines and further advance its proprietary discovery platform.

Moonwalk Biosciences is developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. The Company's proprietary AI-enabled discovery platform integrates human genetics, epigenomics and multi-omics with adipose-selective siRNA chemistry to identify and validate novel therapeutic targets involved in adipose biology, without affecting appetite. Moonwalk is advancing a pipeline of therapies designed to preserve lean mass, improve tolerability and enable infrequent dosing while addressing the underlying biology of obesity and metabolic disease.